Are China's Rising Labor Costs Good For Big Pharma?
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market
You may also be interested in...
Rising Labor Cost Top Risk For Multinationals In China – AmCham Survey
A slowing economy and regulatory uncertainty loom large for multinationals operating in China. However, companies say rising labor costs impact them more, and acute shortages of qualified employees further complicate the landscape.
European Firms May Shift Away From China Due To Tougher Environment – European Chamber Of Commerce Survey
Survey finds lingering challenges and uncertainty despite – and sometimes because – of new government measures.
After Another Strong Quarter, WuXi Aims To Become Backbone Of China’s Life Science Industry: China Earnings Roundup (Part 1)
Despite a macroeconomic slowdown, China’s leading CRO reported another strong quarter due to increasing demand for R&D services from both international and domestic companies.